Spotlight on sirukumab for the treatment of rheumatoid arthritis: The evidence to date

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 3083-3097

  Lazzerini, Pietro Enea ^a   Capecchi, Pier Leopoldo ^a   Guidelli, Giacomo Maria ^a   Selvi, Enrico ^a   Acampa, Maurizio ^b   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Cardiovascular disease; Interleukin 6; Rheumatoid arthritis; Sirukumab; Systemic lupus erythematosus; Tocilizumab

Indexed keywords

ADALIMUMAB; CLAZAKIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MIDAZOLAM; OLOKIZUMAB; OMEPRAZOLE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; SARILUMAB; SIRUKUMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; WARFARIN; MONOCLONAL ANTIBODY;

AREA UNDER THE CURVE; AUTOIMMUNITY; BRAIN ARTERY ANEURYSM RUPTURE; CARDIOVASCULAR DISEASE; DEPRESSION; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GIANT CELL ARTERITIS; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE REACTION; JOINT INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; PLEIOTROPY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMISTRY; DEPRESSIVE DISORDER, MAJOR; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DEPRESSIVE DISORDER, MAJOR; HUMANS; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, INTERLEUKIN-6;

EID: 84989159523     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S99898     Document Type: Review

References (90)

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746): 1094-1108.
2. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7): 1316-1322.
3. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121(10 Suppl 1): S9-S14.
4. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2016. pii: ehw208. Epub June 1, 2016.
5. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11): 3537-3545.
6. Shetty A, Hanson R, Korsten P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014;8: 349-364.
7. Reichert JM. Antibodies to watch in 2016. MAbs. 2016;8(2): 197-204.
8. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2012;122(4): 143-159.
9. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2(4): 288-294.
10. Lazzerini PE, Capperucci C, Spreafico A, et al. Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells. Joint Bone Spine. 2013;80(2): 195-200.
11. van Aken BE, Jansen J, van Deventer SJ, Reitsma PH. Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cells. Blood Coagul Fibrinolysis. 2000;11(2): 159-164.
12. Lazzerini PE, Selvi E, Lorenzini S, et al. Homocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol. 2006;24(4): 387-393.
13. Inoue K, Hosoi J, Denda M. Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes. J Invest Dermatol. 2007;127(2): 362-371.
14. Caporali F, Capecchi PL, Gamberucci A, et al. Human rheumatoid synoviocytes express functional P2X7 receptors. J Mol Med. 2008;86(8): 937-949.
15. Ancey C, Corbi P, Froger J, et al. Secretion of IL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine. 2002;18(4): 199-205.
16. Hou T, Tieu BC, Ray S, et al. Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev. 2008;4(3): 179-192.
17. Trapero I, Cauli O. Interleukin 6 and cognitive dysfunction. Metab Brain Dis. 2014;29(3): 593-608.
18. Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7): 538-542.
19. Febbraio MA, Pedersen BK. Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002;16(11): 1335-1347.
20. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813(5): 878-888.
21. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1): 11-20.
22. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003;300(5628): 2101-2104.
23. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014: article 698313.
24. Conti B, Tabarean I, Andrei C, Bartfai T. Cytokines and fever. Front Biosci. 2004;9: 1433-1449.
25. Onishi K, Zandstra PW. LIF signaling in stem cells and development. Development. 2015;142(13): 2230-2236.
26. Glund S, Krook A. Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol. 2008;192(1): 37-48.
27. Franchimont N, Wertz S, Malaise M. Interleukin-6: an osteotropic factor influencing bone formation? Bone. 2005;37(5): 601-606.
28. Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease. BMB Rep. 2010;43(8): 513-523.
29. Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64(6): 1403-1415.
30. Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863(6 Pt A): 1218-1227.
31. Spooren A, Kolmus K, Laureys G, et al. Interleukin-6, a mental cytokine. Brain Res Rev. 2011;67(1-2): 157-183.
32. Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int. 2010;21(8): 1287-1293.
33. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. 2011;2011: 765624.
34. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6): 784-788.
35. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3): 232-234.
36. Baillet A, Gossec L, Paternotte S, et al. Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort. Arthritis Care Res. 2015;67(7): 905-912.
37. Gottenberg JE, Dayer JM, Lukas C, et al. Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann Rheum Dis. 2012;71(7): 1243-1248.
38. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998;187(4): 461-468.
39. Ohshima S, Saeki Y, Mima T, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A. 1998;95(14): 8222-8226.
40. Patel AM, Moreland LW. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther. 2010;4: 263-278.
41. Hashizume M, Tan SL, Takano J, et al. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. Int Rev Immunol. 2015;34(3): 265-279.
42. Guggino G, Giardina AR, Raimondo S, et al. Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion. Clin Exp Rheumatol. 2014;32(1): 77-81.
43. Thiolat A, Semerano L, Pers YM, et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 2014;66(2): 273-283.
44. Carbone G, Wilson A, Diehl SA, Bunn J, Cooper SM, Rincon M. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci. 2013;9(3): 279-288.
45. Iannone F, Tampoia M, Giannini M, et al. Changes in anti-cyclic citrullinated peptide antibodies and rheumatoid factor isotypes serum levels in patients with rheumatoid arthritis following treatment with different biological drugs. Clin Exp Rheumatol. 2016;34(3): 424-429.
46. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y. Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol. 1995;34(4): 321-325.
47. Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48(6): 1521-1529.
48. Aida Y, Honda K, Tanigawa S, et al. IL-6 and soluble IL-6 receptor stimulate the production of MMPs and their inhibitors via JAK-STAT and ERK-MAPK signalling in human chondrocytes. Cell Biol Int. 2012;36(4): 367-376.
49. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (oxford). 2008;47(11): 1635-1640.
50. Moreland LW, Curtis JR. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin Arthritis Rheum. 2009;39(2): 132-143.
51. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17): 4425-4433.
52. Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15(6): R204.
53. Boekholdt SM, Stroes ES. The interleukin-6 pathway and atherosclerosis. Lancet. 2012;379(9822): 1176-1178.
54. Kleveland O, Kunszt G, Bratlie M, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J. pii: ehw171. Epub May 8, 2016.
55. Chen DY, Chen YM, Hsieh TY, Hsieh CW, Lin CC, Lan JL. Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Res Ther. 2015;17: 52.
56. Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011;219(2): 734-736.
57. McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74(4): 694-702.
58. Makrilakis K, Fragiadaki K, Smith J, Sfikakis PP, Kitas GD. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin Rheumatol. 2015;34(3): 419-427.
59. Ormseth MJ, Yancey PG, Solus JF, et al. Effect of drug therapy on net cholesterol efflux capacity of HDL-enriched serum in rheumatoid arthritis. Arthritis Rheumatol. doi: 10.1002/art.39675. Epub March 18, 2016.
60. Lazzerini PE, Capecchi PL, Acampa M, Galeazzi M, Laghi-Pasini F. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. Autoimmun Rev. 2014;13(9): 936-944.
61. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT syndrome: an emerging role for inflammation and immunity. Front Cardiovasc Med. 2015;2: 26. doi: 10.3389/fcvm.2015.00026.
62. Hagiwara Y, Miyoshi S, Fukuda K, et al. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent I CaL, [Ca2+]i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol. 2007;43(6): 710-716.
63. Mitrokhin VM, Mladenov MI, Kamkin AG. Effects of interleukin-6 on the bio-electric activity of rat atrial tissue under normal conditions and during gradual stretching. Immunobiology. 2015;220(9): 1107-1112.
64. Adlan AM, Panoulas VF, Smith JP, Fisher JP, Kitas GD. Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis. J Rheumatol. 2015;42(3): 421-428.
65. Lazzerini PE, Acampa M, Capecchi PL, et al. Antiarrhythmic potential of anti-cytokine therapy in rheumatoid arthritis: tocilizumab reduces QTc interval by controlling systemic inflammation. Arthritis Care Res (Hoboken). 2015;67(3): 332-339.
66. Mackey RH, Kuller LH, Deane KD, et al. Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women’s health initiative. Arthritis Rheumatol. 2015;67(9): 2311-2322.
67. Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011;72(2): 270-281.
68. Zhuang Y, Xu Z, de Vries DE, et al. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int J Clin Pharmacol Ther. 2013;51(3): 187-199.
69. Zhuang Y, de Vries DE, Xu Z, et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J Clin Pharmacol. 2015;55(12): 1386-1394.
70. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9): 1616-1625.
71. Janssen Research & Development. A study of CNTO 136 (sirukumab), administered subcutaneously, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug (DMARD) therapy (SIRROUND-D). Available from: https://clinicaltrials.gov/ct2/show/NCT01604343?term=NCT01604343&rank=1. NLM identifier: NCT01604343. Accessed August 9, 2016.
72. Akeuchi T, Thorne C, Karpouzas G, et al. Efficacy and safety of sirukimab in patients with active rheumatoid arthritis despite disease-modifying anti-rheumatic drug treatment: results of a randomized, doubled-blind, placebo-controlled study. EULAR; London, UK; 2016: Abstract SAT0145.
73. Janssen Research & Development. A study comparing sirukumab (CNTO 136) monotherapy with adalimumab (HUMIRA®) monotherapy in the treatment of active rheumatoid arthritis (SIRROUND-H). Available from: https://clinicaltrials.gov/ct2/show/NCT02019472?term=NCT02019472&rank=1. NLM identifier: NCT01604343. Accessed August 9, 2016.
74. Janssen Research & Development. A study of CNTO 136 (sirukumab), a human anti-IL-6 monoclonal antibody, administered subcutaneously, in patients with active rheumatoid arthritis despite anti-TNF-alpha therapy (SIRROUND-T). Available from: https://clinicaltrials.gov/ct2/show/NCT01606761?term=NCT01606761&rank=1. NLM identifier: NCT01606761. Accessed August 9, 2016.
75. Janssen Research & Development. A study of CNTO 136 (sirukumab) administered subcutaneously in Japanese patients with active rheumatoid arthritis unresponsive to methotrexate or sulfasalazine. Available from: https://clinicaltrials.gov/ct2/show/NCT01689532?term=NCT01689532&rank=1. NLM identifier: NCT01689532. Accessed August 9, 2016.
76. Janssen Research & Development. Long-term safety and efficacy of sirukumab in participants With RA completing studies CNTO136ARA3002 or CNTO136ARA3003 (SIRROUND-LTE). Available from: https://clinicaltrials.gov/ct2/show/NCT01856309?term=NCT01856309&rank=1. NLM identifier: NCT01856309. Accessed August 9, 2016.
77. Tanaka Y, Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis. 2014;73(9): 1595-1597.
78. Kitani A, Hara M, Hirose T, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol. 1992;88(1): 75-83.
79. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991;147(1): 117-123.
80. Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006;119(3): 296-305.
81. Iwano M, Dohi K, Hirata E, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol. 1993;40(1): 16-21.
82. Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013;65(10): 2661-2671.
83. Rovin B, van Vollenhoven R, Aranow C, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. doi: 10.1002/art.39722. Epub April 25, 2016.
84. Guillevin L, Régent A. Treating giant-cell arteritis: is IL-6 the cytokine to target? Lancet. 2016;387(10031): 1882-1883.
85. GlaxoSmithKline. Efficacy and safety study of sirukumab in patients with giant cell arteritis. Available from: https://clinicaltrials.gov/ct2/show/NCT02531633?term=NCT02531633&rank=1. NLM identifier: NCT02531633. Accessed Aug 9, 2016.
86. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5): 446-457.
87. Hsu B, Wang D, Sun Y, Chen G. Improvement in measures of depressed mood and anhedonia, and fatigue, in a randomized, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 antibody, in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(Suppl 2): 720-721. doi: 10.1136/annrheumdis-2015-eular.4081.
88. Janssen Research & Development. An efficacy and safety study of sirukumab in participants with major depressive disorder. Available from: https://clinicaltrials.gov/ct2/show/NCT02473289?term=NCT02473289&rank=1. NLM identifier: NCT02473289. Accessed Aug 9, 2016.
89. Feaver R, Collado S, Hoang S, et al. The anti-IL-6 antibody sirukumab inhibits vascular inflammation in a human surrogate model of atherosclerosis. 2014 ACR/ARHP Annual Meeting. Abstract number: 439. Available from: http://acrabstracts.org/abstract/the-anti-il-6-antibody-sirukumab-inhibits-vascular-inflammation-in-a-human-surrogate-model-of-atherosclerosis/. Accessed Aug 9, 2016.
90. Feaver R, Collado S, Hoang S, et al. Neutralization of IL6 by sirukumab (SIR) inhibits inflammation and cellular stress in a human vascular surrogate system of atherosclerosis. Ann Rheum Dis. 2015;74: 444-445. doi: 10.1136/annrheumdis-2015-eular.5132.